Medipharm Labs Announces White Label Agreement, Provides No Details

Medipharm Labs (TSX: LABS) has entered into its second white label supply agreement with its Australian counterpart for the New Zealand market. The white label agreement will see the firms Australian division supply Cannasouth Plant Research New Zealand Limited with cannabis oil products.

While Medipharm Labs determined that the contract was material enough to make a news release in relation to it, evidently the specific details of the contract were not. The company identified that the supply agreement will be for a period of two years, with Medipharm supplying GMP certified cannabis oil to Cannasouth. Additionally, Cannasouth will be the exclusive purchaser of “certain formulations and dosage forms.”

And that’s where the details end of the supposedly material contract. It’s unclear what the value of the agreement amounts to, associated quantities agreed to under the agreement, or just what part exactly makes the news overly material for a firm that generated $129.2 million in revenues for 2019.

The supply arrangement itself is contingent on confirmation that products meet quality standards outlined by New Zealand Medicines and Medical Devices Safety Authority, and Cannasouth confirming certain insurance requirements.

Medipharm Labs last traded at $1.82 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Medipharm Labs Sees CEO Pat McCutcheon Step Down From Role, Remain As Chairman

Medipharm Labs (TSX: LABS) this morning announced drastic changes to its leadership role, with the...

Thursday, December 10, 2020, 07:38:42 AM

Australia Becomes First to Reclassify MDMA and Psilocybin As Medicine for Specific Uses

Australia has become the first country in the world to re-classify the psychedelic substances psilocybin...

Monday, February 13, 2023, 03:47:00 PM

PI Financial Discontinues Coverage On Medipharm Labs, Heritage Cannabis

Friday evening following the close of markets, a note was sent out by PI Financials...

Monday, September 28, 2020, 07:42:00 AM